Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIVE trial of sequential obinutuzumab and venetoclax with standard versus MRD-guided venetoclax maintenance in first-line CLL
NL-OMON54803Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Oct 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of obinutuzumab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoint: MRD-negative bone marrow without progression. Started Oct 2016; status: recruiting.
02
Drugs
obinutuzumabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON54803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54803.